Key result
In a decision-analytic model, PPCI offered a 7.9% absolute decrease in 30-day mortality over a pharmaco-invasive strategy for STEMI patients with cardiogenic shock and presumptive COVID-19.
Why the study?
The optimal STEMI treatment strategy during the COVID-19 pandemic is unclear given the potential risk of occupational exposure during PPCI.
Does primary percutaneous coronary intervention (PPCI) improve 30-day mortality compared to a pharmaco-invasive strategy in patients with STEMI during the COVID-19 pandemic?
Does primary percutaneous coronary intervention (PPCI) improve 30-day mortality compared to a pharmaco-invasive strategy in patients with STEMI during the COVID-19 pandemic?
Usual care with PPCI remains the appropriate treatment strategy for most STEMI cases during the COVID-19 pandemic, though a pharmaco-invasive strategy may be considered in selected patients to reduce provider risk.
Answers are grounded in this paper and cite their sources.
May favor PPCI in shocked STEMI with presumptive COVID-19; leaves open prospective validation beyond decision modeling.
BACKGROUND: The optimal treatment strategy for treating ST-segment-elevation myocardial infarction (STEMI) in context of the coronavirus disease 2019 (COVID-19) pandemic is unclear given the potential risk of occupational exposure during primary percutaneous coronary intervention (PPCI). We quantified the impact of different STEMI treatment strategies on patient outcomes and provider risk in context of the COVID-19 pandemic. METHODS: Using a decision-analytic framework, we evaluated the effect of PPCI versus the pharmaco-invasive strategy for managing STEMI on 30-day patient mortality and individual provider infection risk based on presence of cardiogenic shock, suspected coronary territory, and presence of known or presumptive COVID-19 infection. RESULTS: For patients with low suspicion for COVID-19, PPCI had mortality benefit over the pharmaco-invasive strategy, and the risk of cardiac catheterization laboratory provider infection remained very low (<0.25%) across all subgroups. For patients with presumptive COVID-19 with cardiogenic shock, PPCI offered substantial mortality benefit to patients relative to the pharmaco-invasive strategy (7.9% absolute decrease in 30-day mortality), but also greater risk of provider infection (2.3% absolute increase in risk of provider infection). For patients with presumptive COVID-19 with nonanterior STEMI without cardiogenic shock, PPCI offered a 0.4% absolute mortality benefit over the pharmaco-invasive strategy with a 0.2% greater absolute risk of provider infection, and the tradeoff between patient and provider risk with PPCI became more apparent in sensitivity analysis with more severe COVID-19 infections. CONCLUSIONS: Usual care with PPCI remains the appropriate treatment strategy in the majority of cases presenting with STEMI in the setting of the COVID-19 pandemic. However, utilization of a pharmaco-invasive strategy in selected patients with STEMI with presumptive COVID-19 and low likelihood of mortality from STEMI and use of preventive strategies such as preprocedural intubation in high risk patients when PPCI is the preferred strategy may be reasonable to reduce provider risk of COVID-19 infection.
No takes yet. Share an insight, caveat, or question.
Butala et al. (2020) studied ST-segment-elevation myocardial infarction (STEMI) during COVID-19 pandemic. Primary percutaneous coronary intervention (PPCI) vs. Pharmaco-invasive strategy was evaluated on 30-day patient mortality and individual provider infection risk. In a decision-analytic model, PPCI offered a 7.9% absolute decrease in 30-day mortality over a pharmaco-invasive strategy for STEMI patients with cardiogenic shock and presumptive COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: